Notice Information
Notice Title
Molecular Screening
Notice Description
This Prior Information Notice (PIN) is separate to any tender opportunity and its purpose is to consult the market to improve NHSBT's knowledge of current assays and high throughput non-blood donor nucleic acid testing systems available in the marketplace and gauge market interest. It is the intention of NHSBT to further consult those organisations who express an interest to identify preparatory work which may need to take place ahead of any future tendering opportunities.
Lot Information
Lot 1
NHSBT requires a direct contractual relationship with either the manufacturer or any other economic operator for a complete end-to-end integrated solution, which must include all the necessary equipment, installation, maintenance, consumables, reagents, software, including an inter-operability provision with NHSBT's existing IT infrastructure, and an overall on-going support mechanism that may be required to carry out the necessary testing as stated below. All in vitro diagnostic medical devices, for example, instruments, consumables, and reagents must be CE/UKCA marked. Great Britain (GB) will continue to recognise CE marking under the IVDD or IVDR until 30 June 2023 and from 1 July 2023 devices placed on the GB market must be UKCA marked under the UK MDR 2002 as amended. The end-to-end solution must be capable of producing test results in a format that can be utilised by NHSBT's host IT system.
NHSBT are looking for a fully integrated, high throughput, automated Nucleic Acid Testing (NAT) screening system which can detect HBV DNA, HIV-1 RNA, HIV-2 RNA, HCV RNA, HEV RNA in EDTA plasma samples from non-blood (e.g. stem cell, tissue) donors including deceased (non-heart beating) donors.
Molecular Screening will be performed by NHSBTs Microbiology Services Laboratory in Colindale (London) with the following approximate number of samples per marker per year for both donation screening and confirmatory testing:
~ HBV DNA: 7,381 screening tests (see note) & 1,082 discriminatory/ID tests per year.
~HIV-1 RNA/ HIV-2 RNA: 7,381* screening tests & 652 discriminatory/ID tests per year.
~HCV RNA: 7,381 screening tests (se note) & 640 discriminatory/ID tests per year.
~HEV RNA: 7,126 tests per year.
NOTE:HBV/HIV1&2/HCV tested as a multiplex screen.
It is important that interested parties respond to this PIN, as prior KEG approval will be a mandatory requirement for any associated future tender opportunity, in-line with the requirements of the Guidelines for the Blood Transfusion Services in the United Kingdom (Red Book - https://www.transfusionguidelines.org/red-book).
NHSBT will seek to understand the status of assays which would be offered with regards to NHSBT's Kit Evaluation Group (KEG).
Further details on KEG and the process will be provided during Supplier Engagement.
The format of Supplier Engagement will be communicated to those organisations that respond to this PIN; however, this is likely to be virtual meetings conducted via Microsoft Teams during the second half of September 2022.
Expressions of interest should be e-mailed to daniel.kirkbride@nhsbt.nhs.uk by 1200hrs on 12 September 2022.
Notice Details
Publication & Lifecycle
- Open Contracting ID
- ocds-h6vhtk-0363be
- Publication Source
- Find A Tender Service
- Latest Notice
- https://www.find-tender.service.gov.uk/Notice/024061-2022
- Current Stage
- Planning
- All Stages
- Planning
Procurement Classification
- Notice Type
- Planning Notice
- Procurement Type
- Standard
- Procurement Category
- Goods
- Procurement Method
- Not Specified
- Procurement Method Details
- Not specified
- Tender Suitability
- Not specified
- Awardee Scale
- Not specified
Common Procurement Vocabulary (CPV)
- CPV Divisions
33 - Medical equipments, pharmaceuticals and personal care products
85 - Health and social work services
-
- CPV Codes
33100000 - Medical equipments
33124000 - Diagnostics and radiodiagnostic devices and supplies
85111800 - Pathology services
Notice Value(s)
- Tender Value
- £7,000,000 £1M-£10M
- Lots Value
- Not specified
- Awards Value
- Not specified
- Contracts Value
- Not specified
Notice Dates
- Publication Date
- 26 Aug 20223 years ago
- Submission Deadline
- Not specified
- Future Notice Date
- 5 May 2024Expired
- Award Date
- Not specified
- Contract Period
- Not specified - Not specified
- Recurrence
- Not specified
Notice Status
- Tender Status
- Planned
- Lots Status
- Planned
- Awards Status
- Not Specified
- Contracts Status
- Not Specified
Buyer & Supplier
Contracting Authority (Buyer)
- Main Buyer
- NHS BLOOD AND TRANSPLANT
- Contact Name
- Available with D3 Tenders Premium →
- Contact Email
- Available with D3 Tenders Premium →
- Contact Phone
- Available with D3 Tenders Premium →
Buyer Location
- Locality
- BRISTOL
- Postcode
- BS34 7QH
- Post Town
- Bristol
- Country
- England
-
- Major Region (ITL 1)
- TLK South West (England)
- Basic Region (ITL 2)
- TLK5 West of England
- Small Region (ITL 3)
- TLK52 Bath & North East Somerset and South Gloucestershire
- Delivery Location
- Not specified
-
- Local Authority
- South Gloucestershire
- Electoral Ward
- Filton
- Westminster Constituency
- Filton and Bradley Stoke
Further Information
Open Contracting Data Standard (OCDS)
View full OCDS Record for this contracting process
The Open Contracting Data Standard (OCDS) is a framework designed to increase transparency and access to public procurement data in the public sector. It is widely used by governments and organisations worldwide to report on procurement processes and contracts.
{
"tag": [
"compiled"
],
"id": "ocds-h6vhtk-0363be-2022-08-26T21:16:53+01:00",
"date": "2022-08-26T21:16:53+01:00",
"ocid": "ocds-h6vhtk-0363be",
"initiationType": "tender",
"tender": {
"id": "ocds-h6vhtk-0363be",
"legalBasis": {
"id": "32014L0024",
"scheme": "CELEX"
},
"title": "Molecular Screening",
"status": "planned",
"classification": {
"scheme": "CPV",
"id": "33100000",
"description": "Medical equipments"
},
"mainProcurementCategory": "goods",
"description": "This Prior Information Notice (PIN) is separate to any tender opportunity and its purpose is to consult the market to improve NHSBT's knowledge of current assays and high throughput non-blood donor nucleic acid testing systems available in the marketplace and gauge market interest. It is the intention of NHSBT to further consult those organisations who express an interest to identify preparatory work which may need to take place ahead of any future tendering opportunities.",
"value": {
"amount": 7000000,
"currency": "GBP"
},
"lots": [
{
"id": "1",
"description": "NHSBT requires a direct contractual relationship with either the manufacturer or any other economic operator for a complete end-to-end integrated solution, which must include all the necessary equipment, installation, maintenance, consumables, reagents, software, including an inter-operability provision with NHSBT's existing IT infrastructure, and an overall on-going support mechanism that may be required to carry out the necessary testing as stated below. All in vitro diagnostic medical devices, for example, instruments, consumables, and reagents must be CE/UKCA marked. Great Britain (GB) will continue to recognise CE marking under the IVDD or IVDR until 30 June 2023 and from 1 July 2023 devices placed on the GB market must be UKCA marked under the UK MDR 2002 as amended. The end-to-end solution must be capable of producing test results in a format that can be utilised by NHSBT's host IT system.<br/><br/>NHSBT are looking for a fully integrated, high throughput, automated Nucleic Acid Testing (NAT) screening system which can detect HBV DNA, HIV-1 RNA, HIV-2 RNA, HCV RNA, HEV RNA in EDTA plasma samples from non-blood (e.g. stem cell, tissue) donors including deceased (non-heart beating) donors.<br/><br/>Molecular Screening will be performed by NHSBTs Microbiology Services Laboratory in Colindale (London) with the following approximate number of samples per marker per year for both donation screening and confirmatory testing:<br/> ~ HBV DNA: 7,381 screening tests (see note) & 1,082 discriminatory/ID tests per year.<br/> ~HIV-1 RNA/ HIV-2 RNA: 7,381* screening tests & 652 discriminatory/ID tests per year.<br/> ~HCV RNA: 7,381 screening tests (se note) & 640 discriminatory/ID tests per year.<br/> ~HEV RNA: 7,126 tests per year.<br/> NOTE:HBV/HIV1&2/HCV tested as a multiplex screen.<br/><br/>It is important that interested parties respond to this PIN, as prior KEG approval will be a mandatory requirement for any associated future tender opportunity, in-line with the requirements of the Guidelines for the Blood Transfusion Services in the United Kingdom (Red Book - https://www.transfusionguidelines.org/red-book).<br/><br/>NHSBT will seek to understand the status of assays which would be offered with regards to NHSBT's Kit Evaluation Group (KEG).<br/>Further details on KEG and the process will be provided during Supplier Engagement.<br/><br/>The format of Supplier Engagement will be communicated to those organisations that respond to this PIN; however, this is likely to be virtual meetings conducted via Microsoft Teams during the second half of September 2022.<br/><br/>Expressions of interest should be e-mailed to daniel.kirkbride@nhsbt.nhs.uk by 1200hrs on 12 September 2022.",
"status": "planned"
}
],
"items": [
{
"id": "1",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "33124000",
"description": "Diagnostics and radiodiagnostic devices and supplies"
},
{
"scheme": "CPV",
"id": "85111800",
"description": "Pathology services"
}
],
"deliveryAddresses": [
{
"region": "UK"
}
],
"deliveryLocation": {
"description": "Colindale (London)"
},
"relatedLot": "1"
}
],
"communication": {
"futureNoticeDate": "2024-05-06T00:00:00+01:00",
"atypicalToolUrl": "https://health-family.force.com/s/Welcome"
},
"coveredBy": [
"GPA"
]
},
"parties": [
{
"id": "GB-FTS-17015",
"name": "NHS Blood and Transplant",
"identifier": {
"legalName": "NHS Blood and Transplant",
"id": "NHS Blood and Transplant"
},
"address": {
"streetAddress": "500 North Bristol Park",
"locality": "Bristol",
"region": "UKK11",
"postalCode": "BS34 7QH",
"countryName": "United Kingdom"
},
"contactPoint": {
"name": "Daniel Kirkbride",
"telephone": "+44 7764280366",
"email": "daniel.kirkbride@nhsbt.nhs.uk"
},
"roles": [
"buyer"
],
"details": {
"url": "https://www.nhsbt.nhs.uk/",
"buyerProfile": "https://www.nhsbt.nhs.uk/",
"classifications": [
{
"scheme": "TED_CA_TYPE",
"id": "BODY_PUBLIC",
"description": "Body governed by public law"
},
{
"scheme": "COFOG",
"id": "07",
"description": "Health"
}
]
}
}
],
"buyer": {
"id": "GB-FTS-17015",
"name": "NHS Blood and Transplant"
},
"language": "en"
}